Printer Friendly

Tenax Therapeutics Preclinical Studies Show Levosimendan Improves Right Heart Function.

M2 PHARMA-March 6, 2018-Tenax Therapeutics Preclinical Studies Show Levosimendan Improves Right Heart Function


- US-based specialty pharmaceutical company Tenax Therapeutics, Inc. (NASDAQ: TENX) has published positive preclinical data from a study of levosimendan in the March 1, 2018 issue of Pulmonary Circulation, the company said.

The study, conducted by Hansen et al, found that chronic administration of levosimendan improved right heart function and myocardial efficiency in rats with right ventricular failure.

This is the second study published in recent months by Dr. Hansen and colleagues who have investigated the potential benefits of levosimendan treatment for right heart failure secondary to pulmonary hypertension.

Observations from these preclinical studies are in keeping with previous clinical trials of levosimendan in pulmonary hypertension patients that provided evidence that levosimendan may provide benefits to patients with pulmonary hypertension, including those with coexisting right heart failure.

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. Tenax Therapeutics acquired the North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

Tenax Therapeutics is focused on licensing, development, and commercialization of drugs that address conditions with high unmet medical need. Its scientific team includes recognized global experts in pulmonary hypertension.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 6, 2018
Previous Article:Grifols to distribute its saline product in the US via Henry Schein.
Next Article:Hercules Capital Provides Tricida with USD 100m Venture Debt Financing.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters